Multiple sclerosis (MS) is a T-cell-mediated disease of the central nervous system, characterized by damage to myelin and axons, resulting in progressive neurological disability. Genes may influence susceptibility to MS, but results of association studies are inconsistent, aside from the identification of HLA class II haplotypes. Whole-genome linkage screens in MS have both confirmed the importance of the HLA region and uncovered non-HLA loci that may harbor susceptibility genes. In this twostage analysis, we determined genotypes, in up to 672 MS patients and 672 controls, for 123 single-nucleotide polymorphisms (SNPs) in 66 genes. Genes were chosen based on their chromosomal positions or biological functions. In stage one, 22 genes contained at least one SNP for which the carriage rate for one allele differed significantly (Po0.08) between patients and controls. After additional genotyping in stage two, two genes-each containing at least three significantly (Po0.05) associated SNPs-conferred susceptibility to MS: LAG3 on chromosome 12p13, and IL7R on 5p13. LAG3 inhibits activated T cells, while IL7R is necessary for the maturation of T and B cells. These results imply that germline allelic variation in genes involved in immune homeostasis-and, by extension, derangement of immune homeostasis-influence the risk of MS.
Introduction
Multiple sclerosis (MS [MIM 126200; http://www. ncbi.nlm.nih.gov/Omim/]) is a chronic inflammatory disease of the central nervous system (CNS) with a prevalence of about 0.2% among northern Europeans. 1 The disease is characterized by widespread demyelination and axon damage, caused by an abnormal immune response, which lead to a range of neurological disabilities. 2 MS is a complex disease; susceptibility is believed to be conferred by the interplay of several genetic and environmental factors. The importance of the genetic component is illustrated by the fact that the risk of MS in siblings to MS patients is 20-to 40-fold higher than the risk in the general population. 3 Four previous whole-genome linkage screens have suggested the existence of several chromosomal regions containing MS susceptibility genes, yet none of these regions, apart from the HLA region on chromosome 6p21, appears to harbor a major MS susceptibility locus (reviewed in Oksenberg et al 4 ). At the same time, in a recently published meta-analysis that combined raw genotyping data from all published whole-genome linkage screens in MS, it was shown that there exist overlapping regions, which may contain genes predisposing to MS; 5 in addition to the HLA region, regions on chromosome 17q21 and chromosome 22q13 showed suggestive linkage. Similarly, a comparison of the chromosomal locations of susceptibility loci in the human autoimmune diseases MS, type I diabetes mellitus, asthma, Crohn's disease and familial psoriasis and their animal models demonstrated additional regions of overlap; 6 this latter instance of nonrandom clustering supports the notion that susceptibility to clinically distinct autoimmune diseases may be influenced by a common set of genes.
The use of single-nucleotide polymorphisms (SNPs) as genetic markers in association studies has been a successful tool for identifying susceptibility genes in a number of complex diseases including type 1 diabetes mellitus, Crohn's disease and systemic lupus erythematosus. [7] [8] [9] In MS, association studies have investigated both positional candidate genes and functional candidate genes, including genes encoding immunoglobulins and T-cell receptors, HLA molecules and myelin antigens, and chemokines, interleukins and other cytokines; however, to date, with the exception of various HLA class II haplotypes, no candidate gene has reproducibly been shown to be associated with MS. 10 In this study, we have genotyped 123 SNPs, in a total of 66 candidate genes, in up to 672 MS patients and 672 controls, using the Pyrosequencing technique 11 and a two-stage study design. In the first stage, we made use of a limited number of markers and a limited number of patients and controls; in selecting polymorphisms in this stage, we sought to choose exonic SNPs, giving highest priority to SNPs encoding nonsynonymous nucleotide changes. In the second stage of the study, for genes displaying an association to MS in the first stage, we increased both the number of markers in each gene and the number of subjects to be genotyped.
Of the 66 genes investigated, 45 were selected on the basis of their location in regions linked to MS or other autoimmune diseases on chromosomes 5, 7, 12, 17 and 19, [4] [5] [6] and the remaining 21 on the basis either of encoding proteins of potential functional importance in MS, or of having been the focus of previous association studies in MS [12] [13] [14] [15] [16] (Table 1 and Electronic Supplement). To our knowledge, this is the largest association study ever performed in MS on non-HLA loci. Our results suggest that two of the 66 candidate genes-lymphocyteactivation gene-3 (LAG3), on chromosome 12, and the gene encoding the interleukin 7 receptor (IL7R) on chromosome 5-are associated with susceptibility to MS. For both genes, in single-point analysis, carriage counts for one allele of at least three SNPs differed significantly (Po0.05) between MS patients and controls; in addition, in the case of IL7R, predispositional and protective multi-SNP haplotypes were also identified. LAG3 and IL7R encode proteins involved, respectively, in the activation and maturation of lymphocytes; their association with MS suggests that germline allelic variation in genes involved in immune homeostasisand, by extension, derangement of immune homeostasis itself-may influence the risk of this disease.
Results
Single-point analysis of candidate-gene SNPs Of the 66 candidate genes, 34 were genotyped for a single SNP (on account of the scarcity of known SNPs in or near the genes) and 32 for two or more SNPs. In the first stage, we found an association, at the 8% significance level, between SNPs in 22 genes and susceptibility to MS. The power of detecting an odds ratio (OR) of 1.5 in this analysis ranged from 44 to 98%, and for the majority (75%) of SNPs, it exceeded 80%. In order to confirm these results, and to increase the power of detection, a second stage of genotyping was performed on these 22 genes using a larger number of patient and control samples; further, several additional SNPs, located in or around the associated genes, were included in the analysis at this stage.
For 80% of the SNPs studied in stage two, the power of detecting an OR of 1.5 was 80% or more, assuming a twosided significance level of 0.05 (see Electronic Supplement). For two of the 22 genes, LAG3 and IL7R, three or more SNPs were associated with MS at a 5% significance level in single-point analysis of the total case-control data set (Table 2 ). In addition, four SNPs in HAVCR2 were initially found to be associated with MS; however, genotypes for these SNPs did not conform to HardyWeinberg equilibrium (HWE) in the first control set. We thus genotyped the same SNPs in the second control set (which was used for this purpose only); the SNPs were found to conform to HWE in this control set, and there were no significant differences in carriage counts for these SNPs between MS patients and controls in the second set.
Linkage-disequilibrium and haplotype analysis In order to elucidate whether the associations of neighboring SNPs were independent of one another, we performed linkage-disequilibrium (LD) analysis on the two MS-associated genes in the total data set of 672 patients and 672 controls. LD blocks with a |D 0 | value greater than 0.85 were found within IL7R (Tables 3 and  4) ; analysis of LAG3 revealed no such LD blocks within the gene.
We next analyzed whether the distribution of estimated IL7R haplotype counts differed between MS patients and controls (an estimation of haplotype frequencies and counts was performed for SNPs belonging to the same LD block). A significant difference in the haplotype-count distribution was observed, a result that is discussed in more detail below.
MS susceptibility genes: LAG3 and IL7R
In and around LAG3, on chromosome 12p13.32, nine different SNPs were investigated in the second stage of this study ( Figure 1 and Table 2 ); distributions of carriage counts were found to differ significantly between MS patients and controls for three of these SNPsrs19922452, rs951818 and rs870849. The C/T transition encoded by rs870849 in exon 8 gives rise to an aminoacid substitution (Thr455Ile); the T/T genotype was significantly more common in MS patients than in controls (P ¼ 0.026, OR ¼ 1.44; Figure 1 and Table 2 ). The two remaining associated SNPs are located in a noncoding region, approximately 7.9 kilobases downstream of LAG3 and 2.4 kilobases upstream of the gene encoding CD4; these two SNPs are only 137 base pairs apart and are in LD with one other (data not shown). No association was found with six SNPs located downstream of rs870849; two of these SNPs-rs1882545 and rs2365095-are located within introns in LAG3, while the remaining four are located upstream of LAG3. As no LD was found between the associated downstream SNPs and the associated intragenic SNP, no haplotype analysis was performed for LAG3.
The five SNPs studied in IL7R are outlined in Figure 2 . Four of the SNPs are located within the gene, while rs1494571 lies in a downstream flanking region; the intragenic SNPs are both exonic (rs3194051) and intronic (rs987106, rs987107, rs1494554). In an earlier association study of IL7R in MS, which included a scan for novel SNPs, only one of these five SNPs (rs987106) was identified as polymorphic in the investigated casecontrol data set. 17 In the present study, three of five SNPs-rs987106 and rs987107 in intron 6, and rs3194051 in exon 8-were associated with MS. The SNP in exon 8 encodes an amino-acid substitution (Val356Ile) in the Cterminal domain of the translated protein. For all of the associated SNPs, subjects homozygous for the less common allele had a significantly higher risk of MS LAG3 and IL7R are associated with MS Z Zhang et al Table 1 Genes studied in up to 672 multiple sclerosis (MS) patients and 672 controls using single-nucleotide polymorphisms (SNPs) Not genotyped in all samples due to problems with unspecific amplification.
LAG3 and IL7R are associated with MS Z Zhang et al than carriers of the more common allele (Table 2) , suggesting a recessive mode of action for each.
We investigated three five-SNP haplotypes, which together accounted for 99% of IL7R haplotypes in MS patients and 96% in controls, with 100% power; the estimated distribution of the haplotypes differed significantly between patients and controls, and nine out of the haplotypes' 10 possible SNP pairs were found to be in LD with one another (Tables 3 and 4) . Two specific five-SNP haplotypes were also found to be associated with MS: haplotype 1, which was more common in patients (P corrected o0.0005); and haplotype 3 (P corrected ¼ 0.0020), which was more common in controls. Haplotypes 1 and 3 are identical, apart from at the third SNP in the haplotype (rs987106), where haplotype 1 contains T and haplotype 3 A.
Between two of the SNPs included in the investigated IL7R haplotypes, rs1494554 and rs3194051, the |D 0 | value was 0.82, that is, below the designated cutoff value for LD of 0.85; the LD between these two SNPs is in other words strong, but not as strong as that between the other pairs of SNPs in the haplotypes. In addition, we have not been able to demarcate the upstream and downstream boundaries of the LD block. Although there are no known genes in the immediate vicinity of IL7R, there are a number of predicted transcripts; analysis of SNPs from these regions would allow a more precise delineation of the LD block.
Discussion
The field of complex-disease genetics has evolved rapidly during the past 10 years; yet, unfortunately, attempts to identify susceptibility genes have for the most part produced disappointing results. Possible explanations for these failures include population stratification, particularly for studies performed on heterogeneous populations. In MS, many associations of non-HLA candidate genes with disease susceptibility have been reported; few, if any, however, have been convincingly replicated, weakening the evidence for true association. [18] [19] [20] [21] The present study clearly shows the necessity of investigating large data sets in association studies in MS. In the first stage of the study-which employed a liberal, uncorrected significance level of 0.08-22 genes were associated with MS; by expanding the data set in the second stage, we were able to exclude 20 of these genes. In addition, we increased the number of SNPs investigated in the two remaining genes, and analyzed multi-SNP haplotypes, in order to localize with greater power and precision the source of the genetic signal, 22, 23 and in acknowledgment of the fact that haplotypes often encode functional units of protein products.
For many of the SNPs investigated in this study, no difference was observed in the genotype frequencies of cases and controls; however, on account of unpredictable variability of LD throughout the genome, to conclude definitively that the genes in which these SNPs are located do not appreciably increase the risk of MS, it would be necessary to investigate a greater number of polymorphisms in and around the genes (ideally, in an even larger data set). This study was designed with a view to detect genes that increase the risk of MS by a factor of at least 1.5. In MS and other complex disorders, it is to be expected that the ORs associated with certain susceptibility genes will be lower than 1.5; such genes will have remained undetected in the present study. Moreover, on account of genotyping difficulties and low minor-allele frequencies, several of the SNPs in this study failed to reach 80% power. The results of the present association study-to our knowledge, the largest ever performed in MS on LAG3 and IL7R are associated with MS Z Zhang et al candidate genes located outside the HLA regionindicate that two genes, LAG3 and IL7R, are associated with the risk of MS. Both genes contain at least three SNPs that are significantly associated with MS, and in IL7R, predispositional and protective haplotypes were identified. Although LAG3, on chromosome 12p13, and IL7R, on chromosome 5p13, were originally chosen for study on the basis of their location in regions linked to MS and other autoimmune diseases, each gene encodes a molecule involved in T-cell regulation-a process of selfevident importance in the T-cell-mediated disorder MS. LAG3 (CD223) is an MHC class II ligand evolutionarily related to CD4; it downregulates the activated T cells on which it is expressed through a high-affinity interaction with its receptor that blocks the binding of CD4. 24 Experiments in knockout mice have shown that LAG3 negatively regulates both T-cell expansion and the size of the memory-T-cell pool. 25 During inflammation, both LAG3 and MHC class II are strongly upregulated; their interaction may also play a role in the activation of antigen-presenting dendritic cells. 26 The SNP rs870849 in exon 8 of LAG3 encodes a substitution of the nonpolar amino acid isoleucine for the uncharged polar amino acid threonine-a change that could possibly alter the conformational and functional properties of the protein. We speculate that such an alteration might reduce the binding affinity of LAG3, resulting in an enhanced expansion of T cells and a larger memory-T-cell pool-phenomena that could predispose to the development of MS. At the same time, the differences in the distribution of rs870849 genotypes detected in our study between MS patients and controls could be due to the effects of a nearby polymorphism in LD with rs870849 but not investigated in this study.
Since we were unable to demarcate the downstream boundary of the LAG3 association, and since the appealing candidate gene CD4 lies in the vicinity of the associated markers, it remains to be determined whether the polymorphisms responsible for the association are located in LAG3 itself or in CD4.
The interleukin 7 receptor (IL-7R; CD127), a member of the hematopoietin receptor family, is a type 1 membrane glycoprotein capable of binding alpha-helical cytokines. 27 Signalling via IL-7R induces somatic recombination of the T-cell-receptor and immunoglobulin genes, promoting the proliferation and survival of T and B lymphocytes. 28 The IL-7R complex consists of the IL-7R alpha chain and the common cytokine-receptor gamma chain (CD132); the former molecule transduces transmembrane signals through the recruitment of intracellular messengers to its cytoplasmic tail, while the latter activates this transduction.
27,29 IL-7Ra is expressed on immature B cells and T cells; in mice, administration of neutralizing antibodies or genetic ablation of IL7-Ra blocks lymphocyte development. 28 In humans, germline mutations resulting in defective expression of IL-7R give rise to a subtype of the disorder severe combined immunodeficiency.
In the present study, we identified three SNPs associated with MS in IL7R. For a five-SNP LD block (which also contained two unassociated SNPs), we identified one predispositional and one protective haplotype. Interestingly, these two haplotypes differ at only one position-at rs987106, in intron 6 of IL7R-suggesting that a functional consequence of this particular polymorphism may underlie the haplotypes' positive and negative associations with the risk of MS. In a recent array-based study of the expression of over 4000 genes in peripheral-blood mononuclear cells from 15 MS patients and 15 age-and sex-matched controls, IL7R was one of only 25 genes that displayed significantly higher expression in patients; 30 overexpression of IL7R, the authors speculate, may result in increased numbers of autoantigen-specific T cells.
In conclusion, we found associations between two genes and MS. Both genes are involved in regulation of the immune system, and both confer a moderate risk for the development of the disease. These findings are thus in accordance with the polygenic disease model proposed for MS. Further analysis of these genes in other MS data sets, as well as functional studies of the proteins they encode, is of utmost importance for the validation of our results.
Materials and methods

Samples from patients and controls
Blood samples for DNA extraction were collected from 672 Nordic MS patients with a mean age of 45.6 years (range, 15-80 years) and a mean disease duration of 14.1 years (range, 6 months to 63 years). The disease course was primary progressive in 12.1% of patients; 71.6% were female. The mean age of the 672 Nordic controls recruited for this study was 54.5 years (range, 17-91 years); 49.2% were female. MS samples were provided by the Departments of Neurology of Karolinska University Hospital, in Stockholm, Sweden, which also provided samples from a control group consisting of 288 blood donors (Karolinska control group). The remaining 384 controls were randomly selected unrelated members of a set of mono-and dizygotic twin pairs enrolled in the Swedish Twin Registry (Twin Registry control group). The combined Karolinska and Twin Registry control sets are referred to here as the first control set; for reasons explained above, a second control set of 465 Swedish blood donors (mean age, 42.8 years (range, 18-69 years); 42.3% female) was used to evaluate four SNPs in the HAVCR2 gene.
All patients were diagnosed as having clinically or laboratory-supported definite MS, in accordance with the recommendations of Poser and co-workers. 31 Informed consent was obtained from all patients and controls, and the study was approved by the ethical committee of Karolinska University Hospital.
The study was performed in two stages. The first stage included between 149 and 288 MS patients and between 84 and 288 controls. In the event a P-value below 0.08 (w 2 test for carriage of one of the two alleles) was observed for one or more SNPs within in a gene, a second stage of genotyping was performed on that gene using additional patients and controls. (The cutoff P-value was originally set at 0.10. Further genotyping was not performed on three genes with P-values between 0.10 and 0.08 (due to the low prior probability of their association with MS). The de facto cutoff P-value was thus 0.08.) The total number of subjects investigated for such genes, during the two stages of the study, was between 356 and 672 MS patients and between 462 and 672 controls (all from the first control set). In order to preserve DNA, random sets 16 separate polymerase chain reactions (PCRs), resulting in amplicons ranging from 250 to 550 base pairs. Denaturing high-performance liquid chromatography (DHPLC) was then performed using the Transgenomic WAVE System (Transgenomic, Omaha, Neb, USA). PCR products were then loaded onto a preheated reverse-phase column (DNASep; Transgenomic) using an automatic sample injector, and subsequently eluted using an acetonitrile gradient in a 0.1 M triethylamine-acetate buffer (pH 7.0) at a constant flow rate of 0.9 ml/min. Samples detected by DHPLC as being heterozygous were then sequenced using ABI PRISM Big Dye Terminator (Applied Biosystems, Foster City, CA, USA), and the sequencing products analyzed on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems), in order to detect the nature and position of the polymorphism in the amplified fragment. Two novel SNPs, located in noncoding sequences of LAG3, were discovered in this manner; prior to the submission of the present report, these SNPs were registered by others in dbSNP under the identification numbers rs2365095 and rs7488113.
PCR primers were designed using Oligo 5.0 software. 32 Two primers, ranging from 19 to 21 nucleotides in length, were designed for each PCR, and amplified fragments ranged from 80 to 150 base pairs in length (see Electronic Supplement for primer sequences). From each subject 10 ng of genomic DNA was used for each PCR amplification. PCRs were performed in a total volume of 25 ml, containing the following: PCR primers (ThermoHybaid, Ulm, Germany), each at a concentration of 400 nM; dNTPs, each at a concentration of 80 mM; Mg 2 þ , at a concentration ranging from 1.5 to 3.5 mM; and 1 U Amplitaq Gold polymerase in 10 Â PCR Gold buffer (Applied Biosystems). The solution was subjected to PCR conditions consisting of a single cycle at 951C for 3 min (for activation of AmpliTaq Gold), followed by 50 cycles at 951C for 20 s, 55-601C for 20 s, and 721C for 30 s. Amplifications were performed on a PTC-225 DNA Engine Tetrad (MJ Research Inc., Watertown, MA, USA).
All SNPs were genotyped using the Pyrosequencing technique, according to the standard protocol provided by the manufacturer (Pyrosequencing AB, Uppsala, Sweden). 33 Sequencing primers (15 nucleotides) were designed using Oligo 5.0 software. 32 
Statistical analysis
For each SNP, P-values for two-by-two contingency tables comparing carriage counts in patients and controls were calculated by a w 2 test and were not corrected. A single-point power analysis was performed for detecting association in the SNPs using a standard method whereby normality in the logarithm of the OR is assumed; power was calculated assuming a two-sided significance level of 0.05 and one-sided power for detecting an OR of at least 1.5 (or 0.67), in the absence of an adjustment for multiple testing.
For the genes containing SNPs with single-point Pvalues less than 0.05, haplotype maps were constructed, and haplotype frequencies estimated, in the following manner. Pairwise measures of LD were obtained using EH. 34 These measures were used to define blocks of closed gene-centric LD with |D 0 | values greater than 0.85. Markers within the blocks were then used to estimate haplotype frequencies using the SNPHAP program (http://www-gene.cimr.cam.ac.uk/clayton/ software/snphap.txt). Haplotype frequencies were converted into a population contingency table by multiplying the number of alleles measured by the frequency estimate, and the contingency table was tested for significance using the T1 statistic of CLUMP with 10 000 simulations. 35 For the analysis of the distribution of estimated haplotype frequencies, power was calculated, using the EM algorithm 36 and a Monte Carlo approach. 37, 38 The analysis was performed for IL7R only, since it was the only gene for which an LD block spanning adjacent associated SNPs was detected. To test for association at the level of single haplotypes, a variation on the permutation test was used. 37, 38 The test was performed after computation of the likelihood ratio for the collapsed two-by-two contingency table of one haplotype vs the others in cases and controls. P-values were divided by 3, in accordance with the Bonferroni method, as a correction for multiple tests. ORs for individual haplotypes were calculated using the WHAP program (http:// www.genome.wi.mit.edu/~shaun/whap/) with haplotype 3 as reference.
